Today, few studies have focused on the search for endothelial dysfunction in patients with obstructive sleep apnoea hypopnoea syndrome (OSAHS). Currently, there is no known biomarker or biomarker pattern that identifies the presence and/or severity of endothelial dysfunction or its relevance in clinical practice. This fact highlights the need for further study of vascular pathogenesis in OSAHS and the implementation of this knowledge into new treatments and biomarkers. Through an innovative approach in the field of OSA and using OMIC's technology, a biomarker profile will be identified to characterise a molecular signature of endothelial dysfunction in these patients and a cardiovascular risk classification will be established according to the degree of endothelial dysfunction detected.

Likewise, a study of the intestinal microbiota in these patients will be carried out and correlated with a metabolic profile of endothelial dysfunction and/or cardiovascular risk. This study is a translational proposal, with a high transferability, which will shed light on new knowledge criteria in OSA and allow the identification of new therapeutic strategies for personalised treatment to prevent and/or correct endothelial dysfunction in these patients. The availability of these new biomarkers will facilitate the detection of the disease and allow a more accurate follow-up of the patient. This will provide new clinical tools for rapid diagnosis, for disease assessment and for monitoring the effects of treatment. Ultimately it will benefit patients in terms of better management of the disease and eventually improved life expectancy.

This study assesses whether a functional and metabolic profile of endothelial tidal cells is able to predict and identify early the cardiovascular complications that occur in mild-moderate OSA.

The aim of this study is to generate new criteria for understanding OSAHS and to identify new therapeutic strategies that will have a direct impact on improving patients' quality of life. Secondly, it aims to identify new biomarkers to prevent and diagnose early stages of the disease. And finally, it aims to ensure that the knowledge acquired can be applied to routine practice and improve the management of the disease.

The search for new biomarkers in OSA may be of potential commercial interest to diagnostic and pharmaceutical companies.